The study results remove a key regulatory overhang and support the NDA resubmission timeline. Monitor for FDA acceptance of the resubmission and any subsequent PDUFA date. Historical trading patterns on AQST have been volatile post-catalysts, so consider position sizing accordingly.
Price Chart
Executive Summary
Aquestive Therapeutics announced positive topline results from its human factors validation and pharmacokinetic studies for Anaphylm (dibutepinephrine) sublingual film, addressing deficiencies cited in the FDA's January 2026 Complete Response Letter. The revised packaging reduced median pouch-open time from 17 to 3 seconds and cut incorrect film placement by over 80%, while self-administration PK matched clinician-administered levels. The company plans to resubmit the NDA in Q3 2026, significantly de-risking the regulatory path for the first potential non-injectable epinephrine product for anaphylaxis.
Key Facts
- Median time to open pouch improved from 17 seconds to 3 seconds in the new human factors study (N=105 vs prior N=166).
- Participants with difficulty opening pouch dropped from 26/166 to 1/105; incorrect film placement fell from 20/166 to 2/105.
- Self-administered Anaphylm showed geometric mean Cmax of 391.7 pg/mL vs 357.6 pg/mL for clinician-administered, with identical median Tmax of 12 minutes.
- Top-of-tongue misplacement still produced geometric mean Cmax of 112.7 pg/mL and clinically meaningful pharmacodynamic responses comparable to injectable epinephrine.
- No serious adverse events, no film removals, and no administration errors in the PK self-administration arm.
- NDA resubmission on track for Q3 2026, less than eight months after the January 2026 CRL.
Financial Impact
No financial data provided; the filing is a clinical update without revenue, earnings, or guidance figures.
Risk Factors
- FDA may still request additional data or studies despite positive topline results.
- NDA resubmission could be delayed or face unexpected review issues.
- Commercial adoption depends on final FDA approval and market acceptance vs established injectable epinephrine products.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001398733-26-000035 |
| Document: humanfactorspkstudyresul.htm | 0001398733-26-000035 |
| Document: hfandclinicalstudystudys.htm | 0001398733-26-000035 |
| Document: 0001398733-26-000035-index-headers.html | 0001398733-26-000035 |
| Document: 0001398733-26-000035-index.html | 0001398733-26-000035 |
| Document: 0001398733-26-000035.txt | 0001398733-26-000035 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $3.97 (−2.22%) |
Oct 15, 2026 11d ago | Press Release | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $3.97 (−2.22%) |
Oct 14, 2026 12d ago | 8-K | $4.61 $4.08 | ▼ −11.50% | ▼ −11.95% | $3.97 (−13.88%) |
Oct 7, 2026 19d ago | SC 13G | $4.62 $4.61 | ▼ −0.22% | ▲ +0.76% | $3.97 (−14.07%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.62 $4.61 | ▲ +0.22% | ▼ −0.76% | $3.97 (+14.07%) |
Sep 29, 2026 27d ago | 8-K | $4.67 $4.61 | ▼ −1.28% | ▼ −3.23% | $3.97 (−14.99%) |
Sep 25, 2026 4w ago | 8-K | $4.68 $4.55 | ▼ −2.78% | ▼ −2.56% | $3.97 (−15.17%) |
Sep 17, 2026 5w ago | 8-K | $4.66 $4.82 | ▲ +3.43% | ▲ +2.83% | $3.97 (−14.81%) |
Sep 16, 2026 5w ago | Insider Cluster | $4.82 $4.70 | ▼ −2.49% | ▼ −5.05% | $3.97 (−17.63%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.29 $4.80 | ▲ +11.89% | ▲ +13.08% | $3.97 (−7.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers